Skip to main content
. 2022 Nov 21;95(1):e28307. doi: 10.1002/jmv.28307

Table 5.

Univariate and multivariate analyses for risk factors of VZV reactivation following COVID‐19 vaccination

Variables Univariate analysis Multivariate analysis
VZV + (n = 6) VZV−(n = 312) p Value ORs 95%CI p Value
Gender, female, n (%) 6 (100.0) 215 (68.9) 0.183
Age, year, median (IQR) 33 (31−41) 41 (32−52) 0.228
AIIRDs type, n (%)
SLE 3 (50.0) 73 (23.4) 0.150
RA 1 (16.7) 100 (32.1) 0.669
SpA 2 (33.3) 48 (15.4) 0.240
Disease duration, year, median (IQR) 12 (2, 14) 6 (2, 10) 0.336
Medical history, n (%)
Diabetes mellitus 2 (33.3) 8 (2.6) 0.013 20.69 1.08−396.79 0.044
Chronic liver disease 1 (16.7) 10 (3.2) 0.192
Chronic HBV infection 2 (33.3) 7 (2.2) 0.010 24.34 1.27−466.74 0.034
Medications, n (%)
Corticosteroid 3 (50.0) 101 (32.4) 0.397
Hydroxychloroquine 2 (33.3) 127 (40.7) 1.000
Immunosuppressive agents 3 (50.0) 149 (47.8) 1.000
Mycophenolate mofetil 3 (50.0) 30 (9.6) 0.016 40.61 3.33−496.15 0.004
Biological agents 1 (16.7) 85 (27.2) 1.000
JAK inhibitor 1 (16.7) 7 (2.2) 0.159
Prior history of Herpes Zoster, n (%) 2 (3) 110 (35.3) 1.000
Get vaccination of Varicella zoster vaccine, n (%) 0 (0.0) 2 (0.6) 1.000
Get vaccination of Herpes zoster vaccine, n (%) 0 (0.0) 4 (1.3) 1.000

Abbreviations: AIIRDs, Autoimmune inflammatory rheumatic diseases; HBV, Hepatitis B virus; IQR, Interquartile Range; RA, Rheumatoid arthritis; SLE, Systemic lupus erythematosus; SpA, Spondyloarthritis.